H.C. Wainwright lowered the firm’s price target on Lenz Therapeutics (LENZ) to $48 from $56 and keeps a Buy rating on the shares. The firm adjusted its Vizz launch estimates ahead of the company’s Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Lenz Therapeutics announces submission of MAA to U.K.’s MHRA for VIZZ 1.44%
- Lenz Therapeutics Earnings Call: High Spend, Growing Traction
- Lenz Therapeutics price target lowered to $26 from $52 at Citi
- Buy Rating on VIZZ Underscored by Improving Prescription Trends and Long-Term Upside Despite Near-Term Revenue Revisions
- Lenz Therapeutics price target lowered to $29 from $35 at BofA